Bispecific antibodies (bsAbs) enable novel mechanisms of action and/or therapeutic
applications that cannot be achieved using conventional IgG-based antibodies …

Xaluritamig (AMG 509) is a six-transmembrane epithelial antigen of the prostate 1 (STEAP1)–
targeted T-cell engager designed to facilitate lysis of STEAP1-expressing cancer cells, such …

The greatest challenge in cancer therapy is to eradicate cancer cells with minimal damage
to normal cells. Targeted therapy has been developed to meet that challenge, showing a …

Purpose: Safety and efficacy of acapatamab, a prostate-specific membrane antigen (PSMA)
x CD3 bispecific T-cell engager were evaluated in a first-in-human study in metastatic …

Research into bispecific antibodies, which are designed to simultaneously bind two antigens
or epitopes, has advanced enormously over the past two decades. Owing to advances in …

T-cell-engaging bispecific antibody (TCB) therapies have emerged as a promising
immunotherapeutic approach, effectively redirecting effector T cells to selectively eliminate …

Bispecific antibodies (bsAbs) are a class of antibodies that can mediate novel mechanisms
of action compared to monospecific monoclonal antibodies (mAbs). Since the discovery of …

Metastatic castrate resistant prostate cancer (mCRPC) continues to have poor survival rates
due to limited treatment options. Bi-specific T cell engagers (BiTEs) are a promising class of …

Simple Summary The developments of radioligand therapy, immunotherapy, and targeted
chemotherapy have led to dozens of clinical trials targeting tumor-associated surface …

To date, immune targeting agents have provided limited benefits in patients with metastatic
prostate cancer. Bispecific T-cell engagers, especially targeting STEAP1, have shown …